Practice Areas & Industries: Jones Day

 





Group Profile Lawyers in this Group Offices Locations for this Group
 

Practice/Industry Group Overview

As one of few global firms with a full-service IP Practice, and operating as One Firm Worldwide, Jones Day provides clients with access to IP lawyers in the United States, Europe, and Asia who are experienced in litigation, prosecution, licensing and technology transfer, and IP counseling.

With nearly 230 lawyers, many of whom have advanced degrees and industry experience in cutting-edge scientific disciplines, we have the "bench strength" and depth to handle any IP issue imaginable.  Moreover, in this new economic age in which financial responsibility and "no surprises" are now facts of life in the world of corporate legal budgets, we take great pride in working with in-house IP counsel to achieve their desired results in a cost-effective and efficient manner.  Thus, it is not surprising that brand name companies in the U.S. and around the globe, including many Fortune 500 companies, have turned to Jones Day to solve their IP problems and to protect, enhance, and maximize the value of their global IP assets.

In addition, Jones Day Intellectual Property Agency (Beijing) Co., Ltd.  is licensed to handle a wide range of copyright, trademark, and other non-patent intellectual property matters in China.


 
Group Presentations
  2013-2014 Life Sciences Webinar Series: Current Trends and Issues in Venture Capital for Life Sciences Companies, January 15, 2014
2013-2014 Life Sciences Webinar Series: Creating Robust Pipelines: Developing Trends in Life Sciences R&D Strategies Using Options to Acquire, December 11, 2013
2013 Speaker Series: Whose Content Is It Anyway? IP Issues in Social Media, November 20, 2013
2013-2014 Life Sciences Webinar Series: Intellectual Property, Regulatory, and Antitrust Issues in Life Sciences M&A and Capital Markets Transactions, November 13, 2013
 
 
Articles Authored by Lawyers at this office:

Can a Patent Application Violate the Copyright Laws?
Jessica D. Bradley,Edwin L. Fountain, December 19, 2013
Recent decisions from two federal district courts have rebuffed efforts by publishers of scientific journals to claim copyright violations based on the copying of the publishers' articles for purposes of preparing patent applications submitted to the U.S. Patent & Trademark Office...

Supplementary Protection Certificates between Centralization and Decentralizatio: CJEU Decides (or not?) on How Much "Identification" of Active Pharmaceutical Ingredient Is Required in Claims of Basic Patent
Olga Bezzubova,Christian B. Fulda,Bojan Savic, December 17, 2013
On December 12, the Court of Justice of the European Union ("CJEU") issued its decision in the case C-493/12 Eli Lilly and Company Ltd vs. Human Genome Sciences Inc. regarding the question to what extent an active pharmaceutical ingredient ("API") has to be specified in a basic...

FTC Expands Premerger Notification Requirements to Cover Certain Pharmaceutical Patent Licenses
, November 15, 2013
On November 6, 2013, the Federal Trade Commission ("FTC") amended the HSR Act rules to include additional pharmaceutical patent licenses under the premerger notification and waiting period requirements (the "amended rules"). The amended rules specify that an exclusive patent...

EPO Will Allow Payment of Additional Search Fees for European Regional Phase Applications
Olga Bezzubova,Diana C. Leguizamon-Morales, November 01, 2013
Following the recent return to the former practice of filing divisional applications in Europe, another applicant-friendly amendment to the European Patent Convention ("EPC") regulations was made official on October 24, when the European Patent Office ("EPO") published on its...

The EPO Rescinds its Current Practice for Divisional Filings
Diana C. Leguizamon-Morales,Martin Weber, October 23, 2013
The rumors are true: An official notice posted on the website of the European Patent Office ("EPO") on October 18, 2013 confirms that the EPO will change its current practice of forcing applicants to file divisional patent applications within certain two-year time windows.